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Abstract
The group I metabotropic glutamate receptors (mGluR1a andmGluR5) are importantmodu-
lators of neuronal structure and function. Although these receptors share common signaling
pathways, they are capable of having distinct effects on cellular plasticity. We investigated
the individual effects of mGluR1a or mGluR5 activation on dendritic spine density in medium
spiny neurons in the nucleus accumbens (NAc), which has become relevant with the poten-
tial use of group I mGluR based therapeutics in the treatment of drug addiction.We found
that systemic administration of mGluR subtype-specific positive allostericmodulators had
opposite effects on dendritic spine densities. Specifically, mGluR5 positive modulation
decreased dendritic spine densities in the NAc shell and core, but was without effect in
the dorsal striatum,whereas increased spine densities in the NAc were observed with
mGluR1a positive modulation. Additionally, direct activation of mGluR5 via CHPG adminis-
tration into the NAc also decreased the density of dendritic spines. These data provide
insight on the ability of group I mGluRs to induce structural plasticity in the NAc and demon-
strate that the group I mGluRs are capable of producing not just distinct, but opposing,
effects on dendritic spine density.
Introduction
The group I metabotropic glutamate receptors (mGluRs), mGluR1a and mGluR5, are impor-
tant modulators of neural signaling and plasticity. Located primarily on post-synaptic struc-
tures, they couple predominately to Gq G-proteins to activate a number of downstream
signaling pathways that have both acute and long-term effects on neuronal excitability [1].
Given the variety of effects these receptors can have on neural plasticity and their wide expres-
sion throughout the brain, group I mGluRs are involved in virtually all nervous system func-
tions and play important roles in a number of disease states, including drug addiction [2].
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One way group I mGluRs may influence function is by regulating neural structure. In hip-
pocampal neurons, for example, activating group I mGluRs with the pan-specific orthosteric
agonist (S)-3,5-Dihydroxyphenylglycine (DHPG) leads to elongation of dendritic spines and
decreases in spine density, suggesting a weakening and loss of synaptic connections [3–5]. Cor-
related with these structural changes, DHPG induces functional plasticity, leading to the devel-
opment of long-term depression in both hippocampal pyramidal neurons and many other cell
types [2]. This effect of group I mGluR activation on dendritic spine plasticity may have an
important biological role as a mechanism of the normal activity-dependent synaptic remodel-
ing and refinement that occurs as a result of learning or other experiences [5]. Additionally,
group I mGluR regulation of spine structure has been linked to certain disease states. As exam-
ples, dysregulatedmGluR5 signaling underlies spine abnormalities in models of Fragile X syn-
drome [6], and spine loss seen in models of Alzheimer’s disease [7].
Although the two group I mGluRs are closely related and couple to many of the same down-
stream signaling pathways, accumulating evidence demonstrates that mGluR1a and mGluR5
can also have distinct functions [8]. This observation highlights the importance of separately
evaluating the influences of mGluR1a versus mGluR5, especially in regions where they are co-
expressed, on neuronal function.Until now, the majority of studies looking at the effects of
group I mGluRs on structural plasticity have not explored potential differences between these
receptor subtypes. However, recent work examining estrogen effects on dendritic spine densi-
ties in the female nucleus accumbens (NAc) have provided indirect evidence of opposing func-
tions of mGluR1a and mGluR5 in regulating structural changes. In the NAc core (NAcC),
estradiol decreases spine density through an mGluR5 dependent mechanism [9]. Conversely,
in the NAc shell (NAcSh), estradiol increases spine density via mGluR1a, an increase similar to
what has been observed in the hippocampus and hypothalamus [9–11]. The possibility that the
two group I mGluRs are having opposing effects on structural plasticity in the NAc is particu-
larly intriguing as group I mGluR signaling in this region is thought to be heavily involved in
the pathophysiology of addiction, and therapeutics are being developed for addiction that tar-
get the mGluR system [12].
With only ancillary evidence that mGluR1a and mGluR5 can have opposing effects on den-
dritic spine densities in the NAc, we sought to determine the effects of independent activation
of these individual receptors on both spine density and morphology. Experiments were per-
formed in ovariectomized female rats to eliminate estrogen as a source of activation of group I
mGluR signaling [9]. Because of the high specificity and therapeutic potential of mGluR posi-
tive allostericmodulators (PAMs), we first looked at the effects of systemic treatment with an
mGluR5 or an mGluR1 PAM. Direct infusion of a specificmGluR5 agonist into the NAc was
also performed to determine whether local activation of mGluRs was sufficient to alter den-
dritic spines.
Methods
Animals
Female Sprague-Dawley rats (175–200 g) were ovariectomized by Envigo Laboratories (India-
napolis, IN) and arrived fully recovered from the procedure and in good health. Animals were
pair housed and kept under a 14:10 light-dark cycle with lights on at 6 a.m. Food and water
were available ad libitum. Animals were allowed to habituate for five days prior to experimen-
tation. All animal procedures were in accordance with the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals and were approved by the Animal
Care and Use Committee at the University of Minnesota (Animal Welfare Assurance Number
A3456-01).
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Drugs
3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) and (RS)-2-Chloro-5-hydro-
xyphenylglycine sodium salt (CHPG) were obtained from Tocris Bioscience (Minneapolis,
MN). CDPPB was suspended in 0.5%methyl cellulose (w/v in deionizedwater, Sigma-Aldrich,
St. Louis, MO). CHPGwas dissolved in sterile saline. 9H-Xanthene-9-carboxylic acid (4-tri-
fluoromethyl-oxazol-2-yl)-amide (SYN119) was synthesized by EAG Laboratories (Sunnyvale,
CA) and was suspended in 20% 2-hydroxypropyl-β-cyclodextrin (w/v in deionizedwater,
Sigma-Aldrich). For systemic treatments, CDPPB (5–10 mg/kg), SYN119 (10 mg/kg), or their
corresponding vehicles were administered intraperitoneally (i.p.) at a volume of 2 ml/kg. For
site-specific drug administration, CHPG (10 μg/0.5 μl/side) or an equivalent volume of vehicle
was infused directly into the NAc. For all experiments, animals were sacrificed 24 hours after
drug administration and tissue was processed for dendritic spine analysis.
Surgical microinjection procedure
Animals were anesthetizedwith a 2.5–4% isoflurane (Piramal Critical Care, Bethlehem, PA)/
oxygen mixture and placed in a stereotaxic apparatus. Drug or vehicle was injected bilaterally
via a Hamilton microinjection syringe at the following coordinates targeting the core-shell bor-
der: AP: +1.80 mm from bregma, ML: ±1.50 mm from bregma, DV: -6.20 mm from dura. Infu-
sions of 0.5 μl were given manually over the course of 2.5 minutes. The injection needle was
then left in place for an additional 2.5 minutes to allow for diffusion of the drug away from the
needle tip. Animals were given a subcutaneous injection of 2.5 mg/kg ketoprofen 20 minutes
prior to surgery and every 12 hours after surgery to induce analgesia and a subcutaneous injec-
tion of 10 mg/kg Baytril at the time of surgery to prevent infection. Immediately following the
surgery, animals were monitored until they recovered ambulatory posture. Afterwards, animals
were observed for eating, drinking, and or the display of any discomfort. None of the animals
exhibited any symptoms of problems. Location of the injection site was verified following
euthanasia.
Tissue preparation
Tissue was prepared and ballistically labeled with DiI following protocols previously estab-
lished in our lab [9,13]. Twenty-four hours after drug treatment, animals were overdosed with
Beuthanasia-D (0.3 ml i.p.; Schering,Union, NJ) and transcardially perfusedwith 25 mM phos-
phate buffered saline (PBS, pH = 7.2) for 3 minutes followed by 1.5% paraformaldehyde in PBS
for 20 minutes. Brains were removed, coronally blocked, and then post-fixed in 1.5% parafor-
maldehyde for 1 hour before being stored in PBS. Brains were sliced into 200–300 μm sections
through the striatum using a Vibratome (Leica VT1000 S, Buffalo Grove, IL). Sectionswere
stored in PBS until DiI labeling.
DiI labeling
DiI “bullets” were made by dissolving 2 mg DiI (Molecular Probes, Carlsbad, CA) in 100 μl
dichloromethane and applying the solution to 90 mg of 1.3 μm tungsten particles (Bio-Rad,
Hercules, CA). Particles were suspended in 10 ml of 15 mg/ml polyvinylpyrrolidone (PVP)
and sonicated for 10 minutes with intermittent vortexing. The suspension was quickly pulled
through a length of Teftzel tubing (Bio-Rad) pre-treated with PVP and allowed to settle before
the remaining PVP was expelled. The tubing was dried for 20 minutes with nitrogen gas flow
and then cut into 1.3 cm bullets. To deliver the DiI-coated tungsten particles, bullets were
loaded into a Helios Gene Gun (Bio-Rad) with a modified barrel, 40 mm spacer, and 70 μm
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mesh filter. PBS was removed from wells containing brain sections, and one bullet was shot per
section using helium gas at 100 PSI. After shooting, sections were stored overnight in the dark
in PBS and then post-fixed in 4% paraformaldehyde for 1 hour the next day. Sectionswere
mounted on slides and coverslipped with FluorGlo mounting media for lipophilic dyes (Spec-
tra Services,Ontario, NY).
Confocal imaging
Cells were imaged with a Leica TCS SPE confocal microscope (Leica,Manheim, Germany). All
images were taken at a xy pixel distribution of 512 x 512 and a frequency of 400 Hz. Whole
medium spiny neurons were imaged at 20Xmagnificationwith a z-step size of 1 μm and recon-
structed using the Leica LAS AF software to measure the distance from the soma to each den-
dritic segment. Cells were imaged from the NAcC and NAcSh in all experiments, and cells
were also imaged in the dorsolateral caudate for experiments using systemic drugmanipula-
tions. Data from a minimum of 7 animals per treatment group were collected for each experi-
ment (see figure legends for specific group sample sizes). For each animal, each brain region
had a minimum of six dendritic segments imaged for analysis, with two or three distal dendritic
segments (distance of 70–200 μm from the soma) taken from each of two or three cells per
brain region. Distal dendritic segments were chosen for analysis as this dendritic region of
medium spiny neurons receives the majority of inputs from glutamatergic projections to the
NAc [14]. Images of individual dendrites were taken with a 63X oil immersion lens and 5.6
optical zoomwith a z-step size of 0.12 μm.
Quantitation
Confocal images were processed through 3D deconvolution using Autoquant X3 AutoDeblur
software (Media Cybernetics, Bethesda,MD) and reconstructed z-stacks were rendered by the
Surpass module of Imaris software (Bitplane, Inc., St. Paul, Minnesota). Dendrites were manu-
ally traced in the xy plane using the Filament tool and Autodepth function by an investigator
blinded to treatment condition. An accurate reconstruction of the diameter of the dendritic
shaft, spine necks, and spine heads was rendered using the diameter functionwith a contrast
threshold of 0.7. Spine density was calculated by summing the number of spines for the total
dendrite length and then calculating the average spine density/10 μm. Densities were averaged
across each cell and then within each brain region for each animal, providing a region-specific
spine density average for each animal. These averages were then used for statistical comparison
between control and treatment groups. Two morphological characteristics, spine neck length
and head diameter, were also measured from each reconstructed segment. These data were
binned (bin sizes: spine neck length, 0.5 μm; head diameter, 0.1 μm) and then expressed as a
frequency distribution with the number of observations in each bin being divided by the total
number of observations for the segment. Similar to spine density, frequency distributions were
averaged across segments from the NAcC or NAcSh to provide region-specific average fre-
quency distributions for each animal to be used for statistical analysis. Data from each drug
treatment group were collected and analyzed in parallel with its corresponding vehicle control
group as fluctuations in baseline spine density can occur from cohort to cohort [9].
Data Analysis
Data were examined for both univariate and multivariate outliers in SPSS (version 20, SPSS,
Inc. Chicago, IL). After outliers were removed (n = 1 animal per experiment), means were
compared using a Student’s t-test for spine density analysis. For spine morphology analyses,
groups were compared using a two-way ANOVA with main factors of bin and drug treatment,
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followed by Bonferroni post-hoc tests. For all statistical tests, results were considered to be sta-
tistically significant if p< 0.05.
Results
To determine if group I mGluRs can differentially regulate dendritic spine plasticity, we acti-
vated either mGluR1a or mGluR5 using two distinct PAMs and analyzed spine density 24
hours later. This time point was chosen based on previous evidence that group I mGluR-
dependent signaling is responsible for changes in spine density in the NAc 24 hours after
estrogen treatment [9]. For quantification, medium spiny neurons of the NAc and dorsal stri-
atum were ballistically labelled with DiI (Fig 1A) and spines were viewed on individual den-
dritic segments (Fig 1B). We first examined the effect of mGluR5 activity on spine density by
systemically administering (via i.p. injection) the mGluR5 PAM, CDPPB (5 or 10 mg/kg). No
differences were observed between the two doses, and consequently the two groups were
combined. Twenty-four hours after treatment with CDPPB, spine density in the NAcC was
decreasedwhen compared to the vehicle treated group (Fig 2A; t(24) = 2.92, p< 0.05).
CDPPB also decreased dendritic spine density in the NAcSh (Fig 2B; t(24) = 2.44, p< 0.05)
indicating that this effect is not sub-region specific. Importantly, CDPPB administration had
no effect on spine density in the dorsal striatum (t(24) = 0.408, p = 0.69), indicating systemic
administration of CDPPB does not necessarily produce the same responses throughout the
brain. Two components of spine morphology, spine neck length and spine head diameter,
were also measured. CDPPB had no effect on neck length in the NAcC or NAcSh twenty-
four hours after administration or on the overall head diameter mean in the NAcC or
NAcSh. However, the effect of CDPPB on head diameter in both the NAcC and NAcSh var-
ied by bin, as evidenced by a significant drug x bin interaction (NAcC: F(9,216) = 3.12,
p< 0.05; NAcSh: F(9, 216) = 2.15, p< 0.05). Specifically, CDPPB treatment reduced the fre-
quency of spines in the 0.2 μm bin in both subregions (NAcC: t(24) = 3.45, p< 0.05; NAcSh:
t(24) = 3.24, p< 0.05).
Fig 1. Representative images of DiI-labeledneuron and dendritic segment. (A) Low power magnification of a DiI-
labeledmedium spiny neuron, scale bar 50 μm. (B) High power magnification of a reconstructeddendritic segment from a
medium spiny neuron, scale bar 5 μm.
doi:10.1371/journal.pone.0162755.g001
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In the next experiment we increasedmGluR1a activity with i.p. administration of the
mGluR1a PAM, SYN119 (10mg/kg). Twenty-four hours after administration, SYN119
increased spine density in both the NAcC (Fig 3A; t(16) = 2.35, p< 0.05) and NAcSh (Fig 3B;
t(17) = 2.17, p< 0.05), but did not affect spine neck length or head diameter in either of these
regions. Again, mGluR1a modulation had no effect on spine density in the dorsal striatum
(t(17) = 0.79, p = 0.44). Together, these data show that increasing activity of the two group I
mGluRs has opposing effects on spine density within the NAc.
After observingNAc structural changes following systemic mGluRmanipulation, we next
determinedwhether local activation of group I mGluRs was sufficient to produce similar alter-
ations. For this study we chose to focus on the effects of a receptor agonist, rather than a PAM
for two reasons. One, direct activation of the mGluR is a more straightforwardmeans to
manipulate the system than using an allostericmodulator. Two, while there is one report of
PAMs being used via direct injection [15], the solubility requirements of these drugs (i.e. the
vehicle in which they are dissolvedmay affect neuronal function)make their use in direct brain
manipulations technically challenging.Hence, we focused on the effects of an mGluR5 agonist
as no comparable selectivemGluR1a agonist is available. The mGluR5 agonist CHPG (10 μg/
0.5 μl/side) or vehicle was bilaterally injected into the NAc and spine density was examined 24
hours later (Fig 4A). CHPG infusion replicated the effects on spine density seen after CDPPB
treatment, decreasing spine density in both the NAcC (Fig 4B; t(12) = 3.13, p< 0.05) and
NAcSh (Fig 4C; t(11) = 3.98, p< 0.05). CHPG did not affect spine neck length or head diame-
ter in either subregion (Fig 4B and 4C).
Fig 2. Positive modulationofmGluR5decreases spine density in the nucleus accumbens but not in the dorsal striatum. (A)
Twenty-four hours after systemic administration, CDPPB (5–10mg/kg, n = 18 animals) decreased dendritic spine density and frequency of
small head diameter spines (0.2 μmbin) compared to vehicle control (n = 8) in the nucleus accumbens core. CDPPB had no effect on neck
length. (B) Similarly, CDPPB decreased spine density and frequency of small head diameter spines (0.2 μmbin) in the nucleus accumbens
shell, but did not affect neck length. *p < 0.05.
doi:10.1371/journal.pone.0162755.g002
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Discussion
Group I mGluRs modulate excitatory neurotransmission throughout the brain. One way they
affect long-term functioning is by altering dendritic structure. The effects of group I mGluR
modulations on spine plasticity have been widely studied in the hippocampus [3–5], yet their
impact on structural plasticity in other brain regions has received little attention. Furthermore,
indirect evidence suggests that activation of mGluR1a and mGluR5 can have opposite effects
on NAc dendritic spine densities [9]. Here we find that systemic activation of the group I
mGluRs using compounds that directly modulate these receptors have opposing effects on
spine densities. Positive modulation of mGluR5 decreased spine density in both the NAcC and
NAcSh and reduced the frequency of small head diameter spines. In contrast, positive modula-
tion of mGluR1a increased spine density in both of these subregions. To study the local effects
of mGluR signaling on spine plasticity, we found that direct injection of the specificmGluR5
agonist CHPG into the NAc produced the same spine density changes observedwith systemic
administration of the mGluR5 PAM. With no suitable selective agonist, we lacked the tools to
perform a comparable experiment selectively targeting mGluR1a.
These findings fit into an expanding field of literature defining distinct roles for the two
group I mGluRs. The eight mGluR subtypes are grouped by sequence homology, similarity in
downstream signal transduction, and receptor pharmacology. The group I mGluRs, mGluR1a
and mGluR5, are the subtypes that canonically signal through the activation of Gq G-proteins
[1]. Yet, group I mGluR signaling can be highly diverse. Not only is the number of secondmes-
senger cascades these receptors can trigger via Gq vast, but group I mGluRs can also couple to
Fig 3. Positive modulationofmGluR1a increases spine density in the nucleus accumbensbut not in the dorsal striatum. (A)
Twenty-four hours after systemic administration, SYN119 (10mg/kg, n = 10 animals) increased dendritic spine density compared to vehicle
control (n = 9) in the nucleus accumbens core but had no effect on spine length or head diameter. (B) SYN119 also decreased spine density
in the nucleus accumbens shell and did not affect spine length or head diameter. *p < 0.05.
doi:10.1371/journal.pone.0162755.g003
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other G-protein types as well as activate G-protein independent signaling pathways [17].
Hence, the two group I mGluRs can couple to different subsets of downstream signaling effec-
tors, allowing them to have varied signaling and functions [18,19]. Examples of the group I
mGluRs affecting cellular signaling and plasticity in different ways have thus far been found in
the striatum [20], hippocampus [18,21], and globus pallidus [22]. Specifically in the nucleus
Fig 4. ActivationofmGluR5 site-specifically decreases spine density in the nucleus accumbens. (A) Schematic representation of
injection sites of either vehicle (open circles) or CHPG (filled circles). Numbers represent distance from bregma, based on the atlas of
Paxinos andWatson [16]. (B)Twenty-four hours after local microinfusion to the nucleus accumbens, CHPG (10 μg/side, n = 7 animals)
decreased dendritic spine density compared to vehicle control (n = 7) in the nucleus accumbens core but had no effect on spine length or
head diameter. (B) CHPG also decreased spine density in the nucleus accumbens shell and did not affect spine length or head diameter.
*p < 0.05.
doi:10.1371/journal.pone.0162755.g004
Group I mGluRs and Nucleus Accumbens Spine Changes
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accumbens,mGluR1 and mGluR5 have been shown to have distinct roles in regulating neuro-
nal signaling related to psychostimulant use, with mGluR5 activity reducing excitatory neuro-
transmission in an endocannabinoid dependent mechanism prior to cocaine experience and
mGluR1 activity reducing excitatory neurotransmission in a PKC-dependent mechanism after
cocaine exposure [23]. Still, our finding that the two group I mGluRs are having wholly oppo-
site effects on spine plasticity within the same brain region is novel.
For these experiments, we were able to dissectmGluR1a and mGluR5 function by using
receptor-specific pharmacologicalmanipulations. Biologically, it would seem that activation of
these receptors would coincide in cells where they are co-expressed since they are activated by
a common ligand, i.e. glutamate. However, there are multiple biological ways that activation of
single mGluR subtypes could be accomplished. In the rat NAc, mGluR1 and mGluR5 only co-
localize with each other in approximately half of the number of individual spines [24], leaving
the possibility that afferents may often feed into synapses specific to one mGluR subtype.
Another possibility is that specificmGluRs are controlled by glutamate-independentmeans.
Research in our lab has explored one example of this mechanism—the regulation of specific
mGluR activity throughmembrane estrogen receptor signaling [9–11,25–29]. As such, in these
experiments we utilized ovariectomized female rats to eliminate the effects of ovarian hor-
mones on this signaling system. Estradiol regulation of mGluRs is not the only example of
glutamate-independent control of these receptors—cellular prion protein can also act as a
ligand to mGluR5 [7]. In both of these examples, signalingmolecules other than glutamate are
able to specifically activate a single mGluR subtype to initiate a particular line of downstream
signaling.
Systemic administration of ligands to regulate specific group I mGluR subtypes is being
tested therapeutically. Group I mGluR allostericmodulators in particular have been considered
for the treatment of multiple disorders, including drug addiction, where group I mGluRs in the
NAc are thought to play an important role. Up until now, the majority of research has focused
on decreasing group I mGluR activity with negative allostericmodulators (NAMs), and both
mGluR1a and mGluR5 NAMs have been found to decrease drug seeking or drug sensitization
[12]. However, recent findings have shown that positive modulation of mGluR1a with SYN119
can reduce cue-induced relapse after extended abstinence from cocaine [15], differing from the
potentiating effects on drug-seeking seen whenmGluR5 is stimulated [30,31]. The differences
in these results are likely due in large part to differences in the behavioral models and mGluR
interventions being used. However, our results indicate that there are also fundamental differ-
ences in the way that mGluR1a or mGluR5 modulators affect NAc plasticity, and these could
be contributing to different behavioral effects seen with these drugs. This of course, is only part
of the story as the systemic administration of these compounds will have widespread effects
upon the nervous system. For example, here we find that increasedmGluR5 activity influences
NAc spine morphologywith a systemic treatment of CDPPB. As local activation in the NAc
with CHPG did not affect morphology in a similar way, this effectmay be influenced by the
activity of CDPPB in other regions of the brain.
Interestingly, just as mGluR1a and mGluR5 stimulation can have divergent effects on neu-
ronal function, regional differences are also observed.Previous research has shown that
CDDPB administration has no effect on spine density or morphology in the mPFC [32], and
similarly, we find no changes in structure in the caudate with either CDPPB or SYN119. Simi-
larly, estrogen receptors activate mGluR5 signaling in both the female caudate and the NAcC,
but structural changes are only observed in the NAc [9,28]. These site-specificmodifications
may be due to several variables, including intrinsic differences between these brain regions, or
differential effects on afferents to these structures after systemic drug application. Lack of a
structural change in the caudate is not due to an inability of the cells in this region to respond.
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In this regard, psychostimulants are well known to produce changes to dendritic spines in both
the caudate and NAc [33].
Dendritic spines are highly dynamic structures. Here, we found changes in spine density in
the NAc 24 hours after pharmacologicalmanipulation of group I mGluRs, aligning with previ-
ous evidence of estradiol and group I mGluR-induced spine changes at this time point in this
region [9]. However, it is possible these drugsmay have also had transient early effects or more
long-term effects on NAc spine density or morphology. Notably, medium spiny neurons
exhibit both short and long-term structural changes, often studied with drugs of abuse. For
example, single injections of psychostimulants produce acute spine density increases in the
NAc, and this form of short-term plasticity is hypothesized to contribute to long-term plasticity
and persistent, stable spine changes with multiple exposures to drugs of abuse [33,34]. Addi-
tionally, the timing of estradiol-induced changes in dendritic spines across multiple brain
regions are both rapid as well as enduring [10,35,36]. Since the goal of this study was to deter-
mine whether differential group I mGluR activation could have opposing effects on NAc
dendritic spine density or morphology, pursuance of a full time course of mGluR1a- and
mGluR5-induced changes in NAc dendritic spine density and morphology is left for future
studies.
Our findings—that systemic modulation of individual group I mGluRs differentially regu-
lates spine plasticity in the NAc—highlight the distinct features of mGluR1a and mGluR5 activ-
ity. Furthermore, we found that local signaling of mGluR5 is sufficient to bring about structural
changes in the NAc, demonstrating that a group I mGluR can be a direct mediator of structural
plasticity in this region. These differencesmake clear that as research continues on group I
mGluR plasticity in the NAc and on systemic manipulation of group I mGluRs, it will be impor-
tant to separately evaluate the activity of mGluR1a and mGluR5 as they are not interchangeable.
Author Contributions
Conceptualization:RLM PGM.
Formal analysis:KSGDDB LAM.
Funding acquisition:MFO RLM PGM.
Investigation: KSGDDB.
Methodology:KSGDDB RLM.
Project administration:RLM PGM.
Resources:MFORLM PGM.
Supervision:RLM PGM.
Validation: KSG DDB LAMRLM PGM.
Visualization: KSGDDB PGM.
Writing – original draft:KSG LAM.
Writing – review& editing:MFO RLM PGM.
References
1. Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Annu Rev Pharmacol Toxicol. 2010; 50: 295–322. doi: 10.1146/annurev.pharmtox.011008.145533
PMID: 20055706
Group I mGluRs and Nucleus Accumbens Spine Changes
PLOSONE | DOI:10.1371/journal.pone.0162755 September 12, 2016 10 / 12
2. Lüscher C, Huber KM. Group 1 mGluR-dependent synaptic long-termdepression: mechanisms and
implications for circuitryand disease. Neuron. 2010; 65: 445–459. doi: 10.1016/j.neuron.2010.01.016
PMID: 20188650
3. Fujii R, Okabe S, UrushidoT, Inoue K, Yoshimura A, Tachibana T, et al. The RNA binding protein TLS
is translocated to dendritic spines by mGluR5 activation and regulates spinemorphology. Curr Biol.
2005; 15: 587–593. doi: 10.1016/j.cub.2005.01.058PMID: 15797031
4. Vanderklish PW, EdelmanGM. Dendritic spines elongate after stimulation of group 1 metabotropic glu-
tamate receptors in cultured hippocampal neurons. Proc Natl Acad Sci. 2002; 99: 1639–1644. doi: 10.
1073/pnas.032681099PMID: 11818568
5. Wilkerson JR, Tsai N-P, Maksimova MA,Wu H, Cabalo NP, Loerwald KW, et al. A role for dendritic
mGluR5-mediated local translation of Arc/Arg3.1 in MEF2-dependent synapse elimination. Cell Rep.
2014; 7: 1589–1600. doi: 10.1016/j.celrep.2014.04.035 PMID: 24857654
6. DölenG, BearMF. Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile
X syndrome. J Physiol. 2008; 586: 1503–1508. doi: 10.1113/jphysiol.2008.150722 PMID: 18202092
7. Um JW, KaufmanAC, Kostylev M, Heiss JK, Stagi M, Takahashi H, et al. Metabotropicglutamate
receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron. 2013; 79:
887–902. doi: 10.1016/j.neuron.2013.06.036 PMID: 24012003
8. Valenti O, Conn PJ, MarinoMJ. Distinct physiological roles of the Gq-coupled metabotropic glutamate
receptors co-expressed in the same neuronal populations. J Cell Physiol. 2002; 191: 125–137. doi: 10.
1002/jcp.10081 PMID: 12064455
9. Peterson BM,Mermelstein PG, Meisel RL. Estradiol mediates dendritic spine plasticity in the nucleus
accumbens core through activation of mGluR5. Brain Struct Funct. 2014; 1–8. doi: 10.1007/s00429-
014-0794-9
10. ChristensenA, Dewing P, Micevych P. Membrane-initiatedestradiol signaling induces spinogenesis
required for female sexual receptivity. J Neurosci. 2011; 31: 17583–17589. doi: 10.1523/JNEUROSCI.
3030-11.2011 PMID: 22131419
11. HuangGZ,Woolley CS. Estradiol acutely suppresses inhibition in the hippocampus through a sex-spe-
cific endocannabinoid andmGluR-dependent mechanism. Neuron. 2012; 74: 801–808. doi: 10.1016/j.
neuron.2012.03.035PMID: 22681685
12. Olive MF. Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr Drug
Abuse Rev. 2009; 2: 83–989. PMID: 19630739
13. Staffend NA, Meisel RL. DiOlistic labeling of neurons in tissue slices: a qualitative and quantitative anal-
ysis of methodological variations. Front Neuroanat. 2011; 5. doi: 10.3389/fnana.2011.00014
14. Smith DA, BolamPJ. The neural network of the basal ganglia as revealed by the study of synaptic con-
nections of identified neurones. Trends Neurosci. 1990; 13: 259–265. doi: 10.1016/0166-2236(90)
90106-KPMID: 1695400
15. Loweth JA, Scheyer AF, Milovanovic M, LaCrosseAL, Flores-Barrera E,Werner CT, et al. Synaptic
depression via mGluR1 positive allostericmodulation suppresses cue-induced cocaine craving. Nat
Neurosci. 2014; 17: 73–80. doi: 10.1038/nn.3590 PMID: 24270186
16. Paxinos G,Watson C. The rat brain in stereotaxic coordinates: hard cover edition. Academic Press;
2007.
17. HermansE, Challiss RAJ. Structural, signalling and regulatorypropertiesof the group I metabotropic
glutamate receptors: prototypic family C G-protein-coupled receptors. Biochem J. 2001; 359: 465–484.
doi: 10.1042/bj3590465 PMID: 11672421
18. Benquet P, Gee CE, GerberU. Two distinct signaling pathways upregulate NMDA receptor responses
via two distinct metabotropic glutamate receptor subtypes. J Neurosci. 2002; 22: 9679–9686. PMID:
12427823
19. Thandi S, Blank JL, Challiss RAJ. Group-Imetabotropic glutamate receptors, mGlu1a andmGlu5a,
couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling
pathways. J Neurochem. 2002; 83: 1139–1153. doi: 10.1046/j.1471-4159.2002.01217.xPMID:
12437585
20. Bonsi P, Platania P, MartellaG, MadeoG, Vita D, Tassone A, et al. Distinct roles of group I mGlu recep-
tors in striatal function. Neuropharmacology. 2008; 55: 392–395. doi: 10.1016/j.neuropharm.2008.05.
020 PMID: 18602651
21. MannaioniG, MarinoMJ, Valenti O, Traynelis SF, Conn PJ. Metabotropic glutamate receptors 1 and 5
differentially regulate CA1 pyramidal cell function. J Neurosci Off J Soc Neurosci. 2001; 21: 5925–
5934.
22. Poisik OV, MannaioniG, Traynelis S, Smith Y, Conn PJ. Distinct functional roles of the metabotropic
glutamate receptors 1 and 5 in the rat globus pallidus. J Neurosci. 2003; 23: 122–130. PMID: 12514208
Group I mGluRs and Nucleus Accumbens Spine Changes
PLOSONE | DOI:10.1371/journal.pone.0162755 September 12, 2016 11 / 12
23. McCutcheon JE, Loweth JA, Ford KA, Marinelli M,Wolf ME, Tseng KY. Group I mGluR activation
reverses cocaine-induced accumulation of calcium-permeableAMPA receptors in nucleus accumbens
synapses via a protein kinase C-dependent mechanism. J Neurosci. 2011; 31: 14536–14541. doi: 10.
1523/JNEUROSCI.3625-11.2011PMID: 21994370
24. MitranoDA, Smith Y. Comparative analysis of the subcellular and subsynaptic localization of mGluR1a
andmGluR5metabotropic glutamate receptors in the shell and core of the nucleus accumbens in rat
andmonkey. J CompNeurol. 2007; 500: 788–806. doi: 10.1002/cne.21214 PMID: 17154259
25. BoulwareMI,Weick JP, Becklund BR, Kuo SP, GrothRD, Mermelstein PG. Estradiol activates group I
and II metabotropicglutamate receptor signaling, leading to opposing influences on cAMP response
element-binding protein. J Neurosci. 2005; 25: 5066–5078. doi: 10.1523/JNEUROSCI.1427-05.2005
PMID: 15901789
26. Chaban V, Li J, McDonald JS, Rapkin A, Micevych P. Estradiol attenuates the adenosine triphosphate-
induced increase of intracellular calcium through group II metabotropic glutamate receptors in rat dorsal
root ganglion neurons. J Neurosci Res. 2011; 89: 1707–1710. doi: 10.1002/jnr.22718PMID: 21793040
27. Dewing P, BoulwareMI, Sinchak K, ChristensenA, Mermelstein PG, Micevych P. Membrane estrogen
receptor-α interactionswith metabotropic glutamate receptor 1a modulate female sexual receptivity in
rats. J Neurosci. 2007; 27: 9294–9300. doi: 10.1523/JNEUROSCI.0592-07.2007 PMID: 17728443
28. Grove-Strawser D, BoulwareMI, Mermelstein PG. Membrane estrogen receptors activate themetabo-
tropic glutamate receptorsmGluR5 andmGluR3 to bidirectionally regulateCREB phosphorylation in
female rat striatal neurons. Neuroscience. 2010; 170: 1045–1055. doi: 10.1016/j.neuroscience.2010.
08.012 PMID: 20709161
29. Kuo J, HaririOR, Bondar G, Ogi J, Micevych P. Membrane estrogen receptor-α interacts with metabo-
tropic glutamate receptor type 1a to mobilize intracellular calcium in hypothalamic astrocytes. Endocri-
nology. 2009; 150: 1369–1376. doi: 10.1210/en.2008-0994PMID: 18948402
30. Besheer J, Grondin JJM, SallingMC, SpanosM, Stevenson RA, Hodge CW. Interoceptive effects of
alcohol requiremGlu5 receptor activity in the nucleus accumbens. J Neurosci. 2009; 29: 9582–9591.
doi: 10.1523/JNEUROSCI.2366-09.2009 PMID: 19641121
31. Wang X, Moussawi K, Knackstedt L, Shen H, Kalivas PW. Role of mGluR5 neurotransmission in rein-
stated cocaine-seeking. Addict Biol. 2013; 18: 40–49. doi: 10.1111/j.1369-1600.2011.00432.xPMID:
22340009
32. LaCrosseAL, Taylor SB, Nemirovsky NE, Gass JT, Olive MF. mGluR5 positive and negative allosteric
modulators differentially affect dendritic spine density andmorphology in the prefrontal cortex. CNS
Neurol Disord DrugTargets. 2015; 14: 476–485. PMID: 25921744
33. Robinson TE, Kolb B. Structural plasticity associatedwith exposure to drugs of abuse. Neuropharma-
cology. 2004; 47, Supplement 1: 33–46. doi: 10.1016/j.neuropharm.2004.06.025
34. Shen H, Toda S, Moussawi K, Bouknight A, ZahmDS, Kalivas PW. Altered dendritic spine plasticity in
cocaine-withdrawn rats. J Neurosci. 2009; 29: 2876–2884. doi: 10.1523/JNEUROSCI.5638-08.2009
PMID: 19261883
35. Woolley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic
spine density during the estrous cycle in the rat. J CompNeurol. 1993; 336: 293–306. doi: 10.1002/cne.
903360210 PMID: 8245220
36. Tuscher JJ, Luine V, FrankfurtM, Frick KM. Estradiol-mediated spine changes in the dorsal hippocam-
pus andmedial prefrontal cortex of ovariectomized female mice depend on ERK andmTOR activation
in the dorsal hippocampus. J Neurosci. 2016; 36: 1483–1489. doi: 10.1523/JNEUROSCI.3135-15.
2016 PMID: 26843632
Group I mGluRs and Nucleus Accumbens Spine Changes
PLOSONE | DOI:10.1371/journal.pone.0162755 September 12, 2016 12 / 12
